Our objectives were to quantify circulating tumour DNA (ctDNA) levels, assess ctDNA dynamics, and explore how ctDNA ESR1 mutations (ctESR1m) may influence treatment response, as their impact on Irosustat efficacy remains unclear. Here, ESR1 is linked to neoplasm.